1. Catalog
  2. 103: Fundamentals of Ablation
103: Fundamentals of Ablation
Create Account
Availability
On-Demand
Cost
Member: $0.00
Non-Member: $25.00
Patient: $0.00
Associate: $0.00
Student: $0.00
Early Career: $0.00
Industry Rep: $25.00
Credit Offered
0.5 AMA PRA Category 1 Credit
0.5 Attendance Credit
0.5 Participation Credit
  • Description
  • Learning Objectives
  • Accreditation Information
  • Faculty and Disclosures
  • Recommended
With the changing landscape of HCC - new systemic (IO based) therapy and mulitmodal (LRT) therapy are at the forefront. This webinar series is intended to help learners understand basic principles of treatment and how specific treatments strategies are selected for patients with HCC.
Upon completion of this session, participants should be able to:

  • Define patient selection criteria for the different types of ablative therapies
  • Explain the unique circumstances in which one ablative therapy may be beneficial over the other
  • Describe key adverse events for each ablative therapy
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings

Anjana Pillai, MD, FAASLD
Scientific Consultant: Replimune, Genentech, Exelixis, Inc., Eisai, Inc., AstraZeneca, Gilead, Boston Scientific
Medical Advisory Board: AstraZeneca, Genentech
Speakers Bureau: Gilead

Julius Chapiro MD, PhD
Scientific Consultant: Guerbet, Bayer, AstraZeneca, Eisai

Nicole Kim, MD, MPH
Grant/Research Support: Madrigal Pharmaceutical

STAFF:

Steven Folstein, MFA, M Ed.
Nothing to Disclose

Wendy Risso, MPH
Nothing to Disclose

Sally Cook, CMP, CHCP
Nothing to Disclose

Powered By